Your browser doesn't support javascript.
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.
McCaughan, Georgia; Di Ciaccio, Pietro; Ananda-Rajah, Michelle; Gilroy, Nicole; MacIntyre, Raina; Teh, Benjamin; Weinkove, Robert; Curnow, Jennifer; Szer, Jeff; Enjeti, Anoop K; Ross, David M; Mulligan, Stephen; Trotman, Judith; Dickinson, Michael; Quach, Hang; Choi, Phillip; Polizzotto, Mark N; Tam, Constantine S; Ho, P Joy; Ku, Matthew; Gregory, Gareth; Gangatharan, Shane; Hapgood, Greg; Cochrane, Tara; Cheah, Chan; Gibbs, Simon; Wei, Andrew; Johnston, Anna; Greenwood, Matthew; Prince, H Miles; Latimer, Maya; Berkahn, Leanne; Wight, Joel; Armytage, Tasman; Hamad, Nada.
  • McCaughan G; Department of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.
  • Di Ciaccio P; St Vincent's Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
  • Ananda-Rajah M; Department of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.
  • Gilroy N; St Vincent's Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
  • MacIntyre R; Department of Infectious Diseases, Alfred Health and Central Clinical School, Monash University, Melbourne, Victoria, Australia.
  • Teh B; General Medical Unit, Alfred Health, Melbourne, Victoria, Australia.
  • Weinkove R; Centre for Infectious Diseases and Clinical Microbiology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Curnow J; Biosecurity Program, The Kirby Institute, University of New South Wales Sydney, Sydney, New South Wales, Australia.
  • Szer J; National Centre for Infections in Cancer, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.
  • Enjeti AK; Department of Infectious Diseases, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.
  • Ross DM; Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand.
  • Mulligan S; Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.
  • Trotman J; Department of Haematology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Dickinson M; Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
  • Quach H; Sydney Centres for Thrombosis and Haemostasis, Sydney, New South Wales, Australia.
  • Choi P; Clinical Haematology, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Polizzotto MN; Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
  • Tam CS; NSW Health Pathology, John Hunter Hospital, Newcastle, New South Wales, Australia.
  • Ho PJ; Department of Haematology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia.
  • Ku M; School of Medicine and Public Health Faculty of Health and Medicine, University of Newcastle, Newcastle, New South Wales, Australia.
  • Gregory G; Department of Hematology and Bone Marrow Transplantation, Royal Adelaide Hospital, Adelaide, Australia.
  • Gangatharan S; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, South Australia, Australia.
  • Hapgood G; Precision Medicine Theme, South Australian Health and Medical Research Institute, and Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
  • Cochrane T; Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
  • Cheah C; Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Gibbs S; Chronic Lymphocytic Leukaemia Australian Research Consortium (CLLARC), Australia.
  • Wei A; Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
  • Johnston A; Department of Haematology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
  • Greenwood M; Clinical Haematology, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Prince HM; Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
  • Latimer M; Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
  • Berkahn L; Department of Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Wight J; ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia.
  • Armytage T; The National Platelet Research and Referral Centre (NPRC), Canberra, Australian Capital Territory, Australia.
  • Hamad N; Haematology Department, The Canberra Hospital, Canberra, Australian Capital Territory, Australia.
Intern Med J ; 51(5): 763-768, 2021 05.
Article in English | MEDLINE | ID: covidwho-1247194
ABSTRACT
Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 vaccination in patients with haematological disorders. It is our recommendation that patients with haematological malignancies, and some benign haematological disorders, should have expedited access to high-efficacy COVID-19 vaccines, given that these patients are at high risk of morbidity and mortality from COVID-19 infection. Vaccination should not replace other public health measures in these patients, given that the effectiveness of COVID-19 vaccination, specifically in patients with haematological malignancies, is not known. Given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Hematology Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: Oceania Language: English Journal: Intern Med J Journal subject: Internal Medicine Year: 2021 Document Type: Article Affiliation country: Imj.15247

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Hematology Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: Oceania Language: English Journal: Intern Med J Journal subject: Internal Medicine Year: 2021 Document Type: Article Affiliation country: Imj.15247